Angioedema Pipeline, FDA Approvals, Emerging Drugs and Clinical Trials 2023 (Updated)
DelveInsight’s, “Angioedema Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Angioedema pipeline landscape. It covers the Angioedema pipeline drug profiles, including Angioedema clinical trials and nonclinical stage products. It also covers the Angioedema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Angioedema Pipeline Report
- DelveInsight’s Angioedema pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Angioedema treatment.
- The leading companies working in the Angioedema Market include Intellia Therapeutics, Ionis Pharmaceuticals, CSL Behring, KalVista Pharmaceuticals, BioMarin Pharmaceutical, Pharvaris Netherlands B.V., Pharming Group NV, Attune Pharmaceuticals, Astria Therapeutics, Bridge Medicines, CURACLE, CAMP4 Therapeutics, Orchard Therapeutics, and others.
- Promising Angioedema Pipeline Therapeutics in the various stages of development include Lanadelumab, DX-2930 – 300mg/2wk, Icatibant, STAR-0215, Donidalorsen, and others.
- September 2023: Intellia Therapeutics announced a study of phase 1 & 2 clinical trials for Biological NTLA-2002. This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
- September 2023: KalVista Pharmaceuticals Ltd announced a study of phase 3 clinical trials for KVD900 600 mg. This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Request a sample and discover the recent advances in Angioedema Treatment Drugs @ Angioedema Pipeline Report
In the Angioedema pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Angioedema clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Angioedema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Angioedema Overview
Angioedema is defined as “subcutaneous tissues and/or submucosal tissues circumscribed non-pitting edema affecting lips, face, neck, and extremities oral cavity, larynx, and gut.”” It becomes life-threatening when it involves the larynx, while intestinal angioedema is painful and mimics acute abdomen.
Find out more about Angioedema Therapeutics Assessment @ Angioedema Preclinical and Discovery Stage Products
Angioedema Emerging Drugs Profile
- NTLA-2002: Intellia Therapeutics
- Donidalorsen: Ionis Pharmaceuticals
Angioedema Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the Angioedema therapies. The Angioedema companies which have their Angioedema drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals.
Learn more about the emerging Angioedema Pipeline Therapies @ Angioedema Clinical Trials Assessment
Scope of the Angioedema Pipeline Report
- Coverage- Global
- Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Angioedema Companies- Intellia Therapeutics, Ionis Pharmaceuticals, CSL Behring, KalVista Pharmaceuticals, BioMarin Pharmaceutical, Pharvaris Netherlands B.V., Pharming Group NV, Attune Pharmaceuticals, Astria Therapeutics, Bridge Medicines, CURACLE, CAMP4 Therapeutics, Orchard Therapeutics, and others.
- Angioedema Pipeline Therapeutics- Lanadelumab, DX-2930 – 300mg/2wk, Icatibant, STAR-0215, Donidalorsen, and others.
Dive deep into rich insights for new drugs for Angioedema treatment, Visit @ Angioedema Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Angioedema: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Angioedema – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Donidalorsen: Ionis Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PHA 121: Pharvaris
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- NTLA-2002: Intellia Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- STAR 0215: Astria Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Angioedema Key Companies
- Angioedema Key Products
- Angioedema- Unmet Needs
- Angioedema- Market Drivers and Barriers
- Angioedema- Future Perspectives and Conclusion
- Angioedema Analyst Views
- Angioedema Key Companies
- Appendix
For further information on the Angioedema pipeline therapeutics, reach out to Angioedema Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
){kind=link}